ANGPTL3, ANGPTL4, APOA5, APOB, APOC2, APOC3, LDLR, PCSK9, LPL gene variants and coronary artery disease risk

Aim. To study the contribution of rare and low-frequency variants of ANGPTL3, ANGPTL4, APOA5, APOB, APOC2, APOC3, LDLR, PCSK9, LPL genes in assessing the risk of coronary artery disease (CAD) in a cohort of Russian patients with various cardiovascular risks.

Material and methods. The study was conducted on a sample of participants in cohort and epidemiological studies (n=2405). Targeted enrichment of coding sequences and exon-intron regions of nine genes (ANGPTL3, ANGPTL4, APOA5, APOB, APOC2, APOC3, LDLR, PCSK9, LPL) was performed. Genetic diagnostics was carried out by next generation sequencing.

Results. CAD was confirmed in 267 patients (11%). After genetic diagnosis, all patients were divided into three following groups: individuals with previously described genetic variants associated with elevated levels of low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TGs); individuals with genetic variants associated with reduced levels of LDL-C and/or TGs; individuals without genetic variants associated with LDL-C and/or TG levels, or with two or more variants with opposite effects on LDL-C and/or TG levels. Kaplan-Meier method revealed that the groups significantly differ in cumulative risk of CAD (p<0,001 for the log-rank test), the maximum risk was in group 1, and the minimum risk in group 2. When conducting the Cox regression, we found that in persons from group 1, the hazard ratio (HR) for CAD is 2,63 times higher (HR =2,63, 95% confidence interval (CI), 1,6-4,34; p><0,001), and in persons from group 2 lower by 1,88 times (HR =0,53, 95% CI, 0,3-0,98; p=0,042) compared with persons from group 3, adjusted for other CAD risk factors: sex, age, smoking, LDL-C and hypertension. Conclusion. Genetic testing in young patients makes it possible to identify individuals with an increased genetic risk of CAD and to focus preventive and therapeutic measures primarily for this category of patients. Keywords: coronary artery disease, cardiovascular diseases, low-density lipoprotein cholesterol, genetic testing. Relationships and Activities: none. 1National Medical Research Center for Therapy and Preventive Medicine, Moscow; 2Pirogov Russian National Research Medical University, Moscow; 3E. I. Chazov National Medical Research Center of Cardiology, Moscow; 4Lomonosov Moscow State University, Moscow; 5Moscow Institute of Physics and Technology, Dolgoprudny, Russia.><0,001 for the log-rank test), the maximum risk was in group 1, and the minimum risk in group 2. When conducting the Cox regression, we found that in persons from group 1, the hazard ratio (HR) for CAD is 2,63 times higher (HR =2,63, 95% confidence interval (CI), 1,6-4,34; p<0,001), and in persons from group 2 lower by 1,88 times (HR =0,53, 95% CI, 0,3-0,98; p=0,042) compared with persons from group 3, adjusted for other CAD risk factors: sex, age, smoking, LDL-C and hypertension.

Conclusion. Genetic testing in young patients makes it possible to identify individuals with an increased genetic risk of CAD and to focus preventive and therapeutic measures primarily for this category of patients.

1. Russian statistical yearbook. М.:Stat.sb. Rosstat, 2018. p. 694. (In Russ.) ISBN: 978-5-89476-456-6.

2. Boytsov SA, Drapkina OM. Modern content and improvement of high cardiovascular risk strategy in reducing mortality from cardiovascular diseases. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(1):4-6. (In Russ.) doi:10.26442/00403660.2021.01.200543.

3. Boytsov SA, Demkina AE, Oshchepkova EV, et al. Progress and Problems of Practical Cardiology in Russia at the Present Stage. Kardiologiia. 2019;59(3):53-9. (In Russ.) doi:10.18087/cardio.2019.3.10242.

4. Meshkov AN, Shcherbakova NV. Molecular genetic diagnosis of predisposition to the development of coronary heart disease: modern state of the problem. Consilium Medicum. 2016;18(12):22-6. (In Russ.) doi:10.26442/2075-1753_2016.12.22-26.

5. Khera AV, Kathiresan S. Genetics of coronary artery disease: discovery, biology and clinical translation. Nature Reviews Genetics. 2017;18(6):331-44. doi:10.1038/nrg.2016.160.

6. Ramensky VE, Ershova AI, Zaicenoka M, et al. Targeted Sequencing of 242 Clinically Important Genes in the Russian Population From the Ivanovo Region. Frontiers in genetics. 2021;12:709419. doi:10.3389/fgene.2021.709419.

7. Meshkov AN, Ershova AI, Kiseleva AV, et al. The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the Russian Federation: The FH-ESSE-RF Study. Journal of Personalized Medicine. 2021;11(6):464. doi:10.3390/jpm11060464.

8. Meshkov A, Ershova A, Kiseleva A, et al. The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia. Genes (Basel). 2021;12(1):66. doi:10.3390/genes12010066.

9. Trinder M, Li X, DeCastro ML, et al. Risk of premature atherosclerotic disease in patients with monogenic versus polygenic familial hypercholesterolemia. Journal of the American College of Cardiology. 2019;74(4):512-22. doi:10.1016/j.jacc.2019.05.043.

10. Trinder M, Francis GA, Brunham LR. Association of monogenic vs polygenic hypercholesterolemia with risk of atherosclerotic cardiovascular disease. JAMA cardiology. 2020;5(4):390-9. doi:10.1001/jamacardio.2019.5954.